Nina Grasselli Kmet

Encephalitis caused by herpes simplex virus 1 (HSV‐1) has been described in pregnancy, but it’s rare, with less than 20 cases being described in peer‐reviewed literature. Physiologic changes in immune response during pregnancy influence the course of HSV‐1 encephalitis (HSVE) and predispose pregnant women to severe complications. We present a case of herpetic encephalitis in a 12‐weeks pregnant patient. In our patient neurologic condition deteriorated despite early diagnosis, appropriate antiviral and antiepileptic treatment, and suppurative neurocritical care, respectively. Disease progression stopped and the patient’s condition improved after pregnancy termination. Improvement could be a consequence of multiple factors, including delayed therapeutic effect of antiviral treatment, the impact of intensive care management, seizure control, and the possibility of spontaneous recovery as part of the natural disease course, respectively. This case highlights the potential severity of HSV‐1 in early pregnancy and underscores the importance of multidisciplinary management and individualized decision‐making in complex clinical situations.

Background: The emergence of multidrug-resistant Gram-negative bacteria, particularly extended-spectrum β-lactamase (ESBL) and AmpC-producing Enterobacterales, has brought renewed interest in temocillin, a narrow-spectrum β-lactam antibiotic first introduced in the 1980s. Objectives: We aimed to provide a comprehensive overview of the microbiological, pharmacological, and clinical profile of temocillin. Methods: We conducted a narrative review of the literature using the PubMed database to identify relevant studies concerning the microbiology, pharmacokinetics, pharmacodynamics, clinical applications, and safety of temocillin. Results: Temocillin shows strong in vitro activity against ESBL- and AmpC-producing organisms, and partial efficacy against certain Klebsiella pneumoniae carbapenemase (KPC)-producing strains. Its pharmacokinetic and pharmacodynamic characteristics, including β-lactamase stability and low ecological impact, support its use in urinary tract infections, bloodstream infections, intra-abdominal infections, pneumonia, and central nervous system infections. Additionally, evidence supports its utility in outpatient parenteral antimicrobial therapy (OPAT), including subcutaneous administration, and in vulnerable populations such as pediatric, elderly, and immunocompromised patients. Temocillin demonstrates a favorable safety profile, minimal disruption of gut microbiota, and cost-effectiveness. It also exhibits synergistic activity with agents like fosfomycin, further enhancing its clinical value. Most of the current evidence is derived from retrospective and observational studies. Conclusions: Temocillin emerges as a promising carbapenem-sparing option for the treatment of challenging infections caused by multidrug-resistant Gram-negative bacteria.

Invasive fungal infections, particularly those caused by Candida species, represent an increasing cause of hospital-related morbidity and mortality. Most commonly Candida spp. is the causative agent of candidemia and invasive candidiasis. In this report we present a complex case of Candida albicans spondylodiscitis, successfully treated with rezafungin, a new echinocandin suitable for weekly outpatient administration. This case illustrates the first documented use of rezafungin in an outpatient setting for C. albicans spondylodiscitis, demonstrating its potential in managing complex fungal infections.

Background: Patients receiving heart transplantation require lifelong immunosuppression and compared to the general population, they have a more than five times higher chance of acquiring COVID-19, and their mortality rates are higher. The aim of the present study was to estimate the epidemiological and clinical characteristics of COVID-19 in heart transplant recipients (HTRs) in Slovenia to estimate the vaccination rate and evaluate possible vaccination-hesitant subgroups. Methods: All SARS-CoV-2-positive HTRs (N = 79) between 1 March 2020 and 31 December 2023 at the Infectious Diseases Department, University Medical Centre Ljubljana, Slovenia, were included retrospectively. Demographic, clinical and vaccination data were extracted from medical documentation and a statistical evaluation was performed. Results: The observed vaccination rate was 63.3%, but among patients who received transplants before the pandemic, it was statistically significantly higher (p = 0.027). Vaccinated HTRs were statistically significantly older (p = 0.004) and had a significantly higher Charlson Comorbidity Index (p = 0.018). Our results indicate no significant differences between vaccinated and unvaccinated HTRs regarding acute respiratory insufficiency (p = 0.135), length of hospital stay (p = 0.106), intensive care unit admission (0.414) and in-hospital mortality (p = 0.317), but we observed statistically more frequently an asymptomatic course in those vaccinated (p = 0.050), and a longer length of stay in vector vaccine recipients (p = 0.011) and in those not re-vaccinated (p = 0.030). There was a significantly higher re-vaccination rate in males (p = 0.005). Conclusions: An asymptomatic course of COVID-19 was more often observed in vaccinated HTRs. Our findings suggest statistically significant differences in COVID-19 vaccine acceptance rates; younger HTRs and those transplanted after the pandemic are more hesitant to vaccinate, while females accept booster doses less frequently.

Background/Objectives: Patients receiving solid organ transplantation require lifelong immunosuppression, making them more susceptible to COVID-19. Vaccination against COVID-19 is recommended for HTR. The aim of the present study was to compare the course of the disease in vaccinated and unvaccinated HTR hospitalized in a tertiary hospital in Slovenia and to evaluate possible hesitant groups. Methods: All SARS-CoV-2 positive HTR (N=79) between 1 March 2020 and 31 December 2023 at the Infectious Diseases Department, University Medical Centre Ljubljana, Slovenia, were included retrospectively. Demographic, clinical and vaccination data were extracted from medical documentation and statistical evaluation was performed. Results: The vaccination rate in the cohort was 63.3%. We found no statistically significant difference in vaccination rates regarding gender (male 68.4% vs. female 50%, p=0.128), but there was a statistically significant higher revaccination rate in males (male 52.7% vs. female 18.2%, p=0.021). Vaccinated HRT were statistically significantly older than unvaccinated (p=0.000) and had a significantly higher Charlson Comorbidity index (p=0.001). The vaccination rate among patients who received transplants before the pandemic (prior to 2020) was statistically significantly higher (71.7% vs. 46.2%; p=0.027). Conclusions: Our results indicate no significant differences in the clinical course of COVID-19 between vaccinated and unvaccinated HRT regarding acute respiratory insufficiency (ARI), length of hospital stay (LOS), intensive care unit admission and mortality. However, our findings do suggest statistically significant differences in COVID-19 vaccine acceptance rates; younger HRT and those transplanted after the pandemic are more hesitant to vaccination and female HRT accept booster doses less frequently.

Summary Introduction The aim of the present study was to determine the demographic, epidemiological and clinical characteristics of adult patients with tetanus in Slovenia between 2006 and 2021, as well as to determine the therapeutic approaches which have been successfully used in the intensive care unit (ICU) of the Infectious Diseases Department in the University Medical Centre Ljubljana (UMC). Methods We included all adult patients who were treated for tetanus in the ICU of the Department of Infectious Diseases Ljubljana between January 1st, 2006, and December 31th, 2021, in the retrospective study. Available epidemiological and clinical characteristics were reviewed from the medical documentation. Results There were 31 patients included in the study, four (12.9%) males and 27 (87.1%) females. The vast majority of patients required mechanical ventilation (MV) (87.1%) which lasted (± SD) on average 35.4 ± 16.0 days. Autonomic dysfunction was present in 29 (93.5%) patients and was statistically significantly associated with shorter disease evolution (p = 0.005) and presence of healthcare-associated infection (p = 0.020). During the hospitalization, 27 (87.1%) patients acquired at least one healthcare-associated infection, most commonly ventilator-associated pneumonia. The average length of stay in the ICU (± SD) was 42.5 ± 21.3 days. With increasing age, MV lasted statistically significantly longer (p = 0.001), length of stay was longer (p = 0.015), and healthcare-associated infections occurred (p = 0.003) more frequently. Four patients (12.9%) died. Conclusions Although the tetanus incidence rate in Slovenia is high in comparison to other European countries on average, our therapeutic approach resulted in a good survival rate and low mortality.

Introduction: In Slovenia national strategies to prevent hepatitis B virus (HBV) infection in children were introduced in the mid-nineties. The aim of the present study was to analyze the epidemiological characteristics of chronic hepatitis B infection in children in Slovenia after the introduction of mandatory HBV vaccination of children and mandatory screening of pregnant women for HBV surface antigen (HBsAg) with consecutive active and passive immunization of newborns of HBsAg-positive mothers. Methods: Children from all regions of Slovenia whose blood samples tested positive for HBsAg at the national reference laboratory for viral hepatitis between January 1997 and December 2010 were included. Demographic, epidemiological and virological data were reviewed retrospectively. Statistical evaluation of the patients’ characteristics was performed and possible trends during the observation period determined. Results: Among 52 HBsAg-positive children, there were 22 (42.3%) girls and 30 (57.7%) boys. Among 40 children tested for HBeAg, 17 were positive (42.5%). The most frequent risk factor for acquiring HBV infection was “presence of HBV infection within the family” (24/35; 68.8%). A significant association between the presence of HBeAg and a viral load of >20,000 IU/ml was found (p=0.001). The difference in the proportion of children of Slovenian origin born before 1994 and after was statistically significant (p=0.039). A statistically significant negative linear trend of the number of diagnosed children in the observed period was found (p=0.006). Conclusions: Prevention strategies adopted in the mid-nineties have resulted in the elimination of chronic hepatitis B in children of Slovenian origin born in Slovenia.